FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| washington, | D.C. | 20549 |  |
|-------------|------|-------|--|
|             |      |       |  |

| <b>STATEMENT</b> | <b>OF CHANGES</b> | IN BENEFICIAL | . OWNERSHIP |
|------------------|-------------------|---------------|-------------|

| OMB APPROVAL             |           |  |  |  |  |  |  |  |  |
|--------------------------|-----------|--|--|--|--|--|--|--|--|
| OMB Number:              | 3235-0287 |  |  |  |  |  |  |  |  |
| Estimated average burden |           |  |  |  |  |  |  |  |  |
| hours per response.      | 0.5       |  |  |  |  |  |  |  |  |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

|   |           |            |                              |  |                                |  |                |                   |  |       |  |   |   | -  | T                                     |  |                                 |   |            |  |  |
|---|-----------|------------|------------------------------|--|--------------------------------|--|----------------|-------------------|--|-------|--|---|---|--|---------------------------------------|--|---------------------------------|---|------------|--|--|
| 1. Name and Address of Reporting Person*  |           |            |                              | 2. Issuer Name and Ticker or Trading Symbol LEMAITRE VASCULAR INC [ LMAT ] |                                |  |                |                   |  |       |  |   | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) |  |                                       |  |                                 |   |            |  |  |
| Roberts   | s David B | <u> </u>   |                              |  | 1                              | LEWATTRE VASCOLAR INC [ LWAT ]                                 |                |                   |  |       |  |   | 2   | X Director   |                                       | ,<br>10% Owi   |                                 | vner  |            |  |  |
|   |           |            |                              |  | -                              |  |                |                   |  |       |  |   | ٠,  |  | (give title                           |  | Other (s                        | specify   |            |  |  |
| (Last)  | •         | ,          | (Middle)                     |  |                                | 3. Date of Earliest Transaction (Month/Day/Year)               |                |                   |  |       |  |   |   | A below) below)  President and Director              |                                       |  |                                 |   |            |  |  |
| C/O LEMAITRE VASCULAR, INC.   |           |            |                              |  | 12/.                           | 12/22/2022   |                |                   |  |       |  |   |   | President and Director                               |                                       |  |                                 |   |            |  |  |
| 63 SECC   | ND AVEN   | UE         |                              |  |                                |  |                |                   |  |       |  |   |   | _  |                                       |  |                                 |   |            |  |  |
| (Otro1)   |           |            |                              |  | 4. If                          | Amer   | ndmen          | t, Date o         | of Original  | Filed | (Month/D   | ay/Year)  |   | 6. In<br>Line  |                                       | Joint/Group  | Filing                          | (Check Ap   | plicable   |  |  |
| (Street)  | GTON M    | Δ          | 01803                        |  |                                |  |                |                   |  |       |  |   |   | - 1  | ,                                     | filed by One   | Repo                            | rting Perso   | n          |  |  |
|   | GTON W    |            | 01005                        |  |                                |  |                |                   |  |       |  |   |   |  | Form filed by More than One Reporting |  |                                 |   |            |  |  |
| (City)  | (S        | tate) (    | (Zip)                        |  |                                |  |                |                   |  |       |  |   |   | Person   |                                       |  |                                 |   |            |  |  |
|   |           | Tab        | le I - Noi                   | n-Deriv  | ative                          | Sec  | uriti          | es Acc            | quired,  | Dis   | posed o  | of, or E  | Bene  | ficiall  | y Owned                               | t  |                                 |   |            |  |  |
| Date  |           |            | 2. Trans<br>Date<br>(Month/I |  | Execution D<br>ay/Year) if any |  | xecution Date, |                   | Transaction Code (Instr.   |       | 4. Securities Acquired (A)<br>Disposed Of (D) (Instr. 3,<br>5) |   |   |  | es<br>ially<br>Following              | Form:  | : Direct<br>Indirect<br>str. 4) | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership |            |  |  |
|   |           |            |                              |  |                                |  |                |                   | Code   | v     | Amount   | (A)<br>(D)  | or  | Price  | Reporte<br>Transac<br>(Instr. 3       | ction(s)   |                                 |   | (Instr. 4) |  |  |
| Common Stock 12/22  |           |            | 2/2022                       | 2022   |                                | М  |                | 17(1)             | 1  | 4     | <b>\$0</b> <sup>(1)</sup>                                      | 16,874  |   | D  |                                       |  |                                 |   |            |  |  |
| Common Stock 12/22/   |           |            | 2/2022                       | /2022  |                                |  | F              |                   | 132 <sup>(2)</sup> D \$  |       | \$45.94  | .94 16,742  |   | 42 D   |                                       |  |                                 |   |            |  |  |
|   |           | Т          | able II -                    |  |                                |  |                |                   |  |       |  |   |   |  | Owned                                 |  |                                 |   |            |  |  |
|   |           |            |                              | (e.g., p   | uts, e                         | calls  | , war          | rants,            | option   | ıs, c | onverti  | ble se  | curit   | ties)  |                                       |  |                                 |   |            |  |  |
| Derivative   Conversion   Date   Execution Date,   Security   or Exercise   (Month/Day/Year)   if any |           |            |                              | ransaction of Eode (Instr. Derivative (                                    |                                | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) |                |                   | 7. Title and<br>Amount of<br>Securities<br>Underlying<br>Derivative Secu<br>(Instr. 3 and 4) |       |  | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) |   | Owners<br>Form:<br>Direct (<br>or Indir<br>(I) (Inst | Ownership                             | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |                                 |   |            |  |  |
|   |           |            |                              |  |                                |  |                |                   |  |       |  |   | or  |  |                                       |  |                                 |   |            |  |  |
|   |           |            |                              |  | Code                           | v  | (A)            |                   | Date<br>Exercisab  |       | xpiration<br>ate   | Title   | of  | umber<br>f<br>hares                                  |                                       |  |                                 |   |            |  |  |
| Dividend<br>Equivalent<br>Rights  | (3)       | 12/22/2022 |                              |  | M                              |  |                | 17 <sup>(3)</sup> | (3)  | T     | (3)  | Commo<br>Stock                                      |   | 17   | \$0                                   | 0  |                                 | D   |            |  |  |

## **Explanation of Responses:**

- 1. Represents shares acquired upon release of dividend equivalent rights, as reported in Table II, on a one-for-one basis.
- 2. These shares represent shares withheld by the Issuer to satisfy tax withholding obligations incurred upon the vesting of restricted stock units awarded to the reporting person on December 22, 2017. This transaction is considered an exempt sale pursuant to Rule 16b-3(e) promulgated under the Securities Exchange Act of 1934.
- 3. These dividend equivalent rights were released in connection with the vesting of a restricted stock unit award granted on December 22, 2017. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

/s/ Laurie A. Churchill,

12/27/2022

Attorney-in-fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.